Tag: pharmaceuticals
-
Orphan Status Assigned to Kidney Disorder RNA Therapy
21 July 2014. Regulus Therapeutics Inc. in San Diego says the U.S. Food and Drug Administration designated its RNA therapy for Alport syndrome, a rare genetic kidney disease, an orphan drug. The therapy, code-named RG-012, shows promise in preclinical studies, including with lab mice. Alport syndrome affects about 1 in 50,000 newborns, a condition that…
-
Immunocore, Lilly Collaborate on T-Cell Cancer Therapies
16 July 2014. Drug maker Eli Lilly and Company in Indianapolis and Immunocore Ltd., a biotechnology company in Oxford, U.K. are jointly discovering new cancer therapies based on T-cells in the body’s immune system. The deal will pay Immunocore $15 million for each new therapy identified, with additional payments of $10 million for each therapy…
-
Dengue Vaccine Shown to Cut Infections, Hospitalizations
11 July 2014. A large-scale clinical trial of a vaccine by the pharmaceutical company Sanofi shows the vaccine prevents symptomatic dengue cases by more than half, with severe forms and hospitalizations from the disease reduced even further. Findings from the study, conducted among more than 10,000 children in five Asian countries, are reported online today…
-
Baxter Acquires Sickle-Cell Prevention Drug Developer
10 July 2014. Baxter International in Deerfield, Illinois is acquiring AesRx LLC, a biopharmaceutical company in Newton, Massachusetts developing drugs for sickle-cell and other rare diseases. Baxter is making an initial payment to AesRx, which will be eligible for future payments tied to development and commercial milestones, but dollar amounts were not disclosed. Sickle cell…
-
Personal Leukemia Immunotherapy Given Breakthrough Status
7 July 2014. The U.S. Food and Drug Administration designated as a breakthrough a personalized immunotherapy developed by University of Pennsylvania in Philadelphia to treat acute lymphoblastic leukemia that does not respond to other treatments or has relapsed. FDA assigns a breakthrough designation and accelerates review of drugs or biologic therapies that treat a serious…
-
University Offers Tuberculosis Drug Technology for Licensing
2 July 2014. A new process for developing drugs for tuberculosis designed at ETH Zurich, the Swiss Federal Institute of Technology, is offered for licensing by the university to companies for commercialization. The technology that aims to overcome resistance to many current tuberculosis drugs is the result of research from the lab of Zurich pharmaceutical…
-
Health Quality Agency: Vaccines Safe, Adverse Effects Rare
1 July 2014. The Agency for Healthcare Research and Quality, a division of the U.S. Department of Health and Human Services, issued a report today indicating a systematic review of published research shows that vaccines are safe and serious adverse reactions to vaccines are rare occurrences. The study, conducted by the Southern California Evidence-Based Practice…
-
Online Clinical Trial with Children Tests Autism Therapy
30 June 2014. Researchers at University of California in San Francisco and Kennedy Krieger Institute in Baltimore completed a clinical trial conducted entirely online testing the ability of omega-3 fatty acids to control hyperactivity in children with autism. The team led by UC-San Francisco medical professor Stephen Bent published its findings in this month’s issue…
-
Late Trial Testing Topical Gel for Diabetic Nerve Pain
26 June 2014. A late-stage clinical trial testing a topical gel to treat diabetic nerve pain completed its enrollment, according to BioDelivery Sciences International in Raleigh, North Carolina, the study’s sponsor. The trial is the first of two clinical studies of Clonidine Topical Gel in preparation for the company’s new drug application with the U.S.…
-
Early Trial Shows Neural Regrowth Effects on Depression
25 June 2014. An early-stage clinical trial by Neuralstem Inc. in Germantown, Maryland provides evidence its experimental drug to treat major depressive disorder is having a positive impact on patients’ brain activity and behavior. The company reported the findings yesterday at a meeting of the International College of Neuropsychopharmacology in Vancouver, Canada, and last week…